Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04304300
Other study ID # NL69780.078.19
Secondary ID Netherlands Tria
Status Recruiting
Phase
First received
Last updated
Start date December 10, 2019
Est. completion date May 2026

Study information

Verified date March 2020
Source Erasmus Medical Center
Contact Jaap Jaspers, MD
Phone 107042982
Email j.jaspers@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rationale: Standard postoperative treatment of isocitrate dehydrogenase 1/2 mutated grade 2 and 3 glioma (IDHmG) consists of radiotherapy and chemotherapy. The improving prognosis of these patients leads towards more emphasis on the long-term effects of treatment. Specifically radiotherapy has been implicated in the development of delayed neurocognitive deterioration. The impact of modern radiotherapy techniques (such as intensity modulated radiotherapy, volumetric modulated radiotherapy and proton beam therapy) and chemotherapy on general toxicity, late neurocognitive outcomes and imaging changes is currently unclear.

Objectives:

- To report treatment outcomes and radiation-induced toxicity from a prospective, multicentre observational cohort of IDHmG patients treated with radiotherapy and chemotherapy,

- To integrate radiotherapeutic dose distributions, imaging changes and neuropsychological outcome in IDHmG.

- To evaluate the Dutch selection criteria for proton therapy applied to IDHmG based on the outcomes collected in this observational study.

- To assess the impact of proton and photon therapy on health-related quality of life (HRQoL) and health-related economics (HR-E) in IDHmG patients.

- To collect genetic material for future translational research into the interaction between germline DNA, prognosis and radiation-induced toxicity.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: This project is a multicentre, observational cohort of patients undergoing radiotherapy and chemotherapy for IDHmG. The protocol closely follows the local guidelines for clinical follow-up. Specific to the study are extra questionnaires and specific imaging acquired during scheduled MRI's. Routine neuropsychological investigation is standard of care in Erasmus Medical Center (Erasmus MC), but not in all participating centers. We feel the additional burden of participation in this study to be low.


Recruitment information / eligibility

Status Recruiting
Enrollment 79
Est. completion date May 2026
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed glioma, World Health Organisation (WHO) grade 2 or 3, IDH mutated

- Indication for standard treatment with radiotherapy and chemotherapy. For WHO grade 2 tumors 50.4 Gy relative biological equivalent (RBE) in 28 fractions. For WHO grade 3 tumors 59.4 Gy (RBE) in 33 fractions.

- Ability to comply with the protocol, including neuropsychological testing and imaging.

- Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.

- Written informed consent.

Exclusion Criteria:

- Any prior chemotherapy for IDHmG. This includes upfront postoperative chemotherapy.

- Any prior cranial radiotherapy, including but not limited to radiotherapy for IDHmG.

- Prior invasive malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with current prostate specific antigen (PSA) of less than or equal to 0.1 ng/mL).

- Extensive white matter disease visible on pre-therapy imaging (Fazekas grade =2)

- Contra-indication for magnetic resonance (MR) imaging (i.e. metal implants, claustrophobia)

- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule in the participating hospitals

- Any other serious medical condition that could interfere with follow-up.

- Severe aphasia or language barrier interfering with assessing endpoints (i.e. completion of questionnaires or neurocognitive performance)

Study Design


Locations

Country Name City State
Netherlands Amsterdam UMC Amsterdam
Netherlands HollandPTC Delft
Netherlands Leiden University Medical Center Leiden
Netherlands Haaglanden Medical Center Leidschendam
Netherlands Erasmus MC Rotterdam Zuid Holland

Sponsors (6)

Lead Sponsor Collaborator
Erasmus Medical Center Amsterdam University Medical Center, Delft University of Technology, HollandPTC, Leiden University Medical Center, Medical Center Haaglanden

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Radiological data If feasible, pre- and 4 months post-treatment a scan protocol will be used that, besides the standard clinical imaging, will focus on (micro-)structural and microvascular characteristics that could predict neurocognitive outcome and treatment efficacy. This feasibility is site-specific. 4 months
Primary Toxicity (selected CTCAE 5.0 items) The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 displays Grade 1 to 5, ranging from 'mild' to 'death'. The case report form will include a predefined set of CTCAE items of expected radiotherapy related toxicities. In addition, other CTCAE toxicities grade = 2 that are likely, possibly or definitely related to the radiotherapy should be recorded in the case report form (CRF), when they occur. All items will include a causality assessment: likely or definitely attributable to radiotherapy, unrelated or unlikely attributable to radiotherapy, or not assessable. 24 months
Primary Neurocognitive testing Neurocognitive functioning will be assessed with a standard and well established short neuropsychological test battery, developed for use in clinical trials. The following tests are included: Hopkins Verbal Learning Test (HVLT), Trail Making Test part A and B (TMT A/B), Controlled Oral Word Association (COWA), Medical Outcomes Study Cognitive Functioning Scale (MOS), Diagnostic Instrument for Mild Aphasia (DIMA) 24 months
Secondary Next intervention free survival (NIFS) NIFS is defined as time from first irradiation to date of initiation of further treatment after radio- and/or chemotherapy or death (any cause), whichever occurs first. 48 months
Secondary Progression Free Survival (PFS) PFS is defined as the time from first irradiation to progressive disease, according to (any of) the Response Asessment in Neuro Oncology (RANO) criteria for progressive disease in low grade glioma. 48 months
Secondary Overall Survival (OS) OS is defined as time from first irradiation to date of death from any cause. 48 months
Secondary Health Related Quality of Life (HRQOL) HRQoL will be assessed with the EORTC quality of life questionnaire (QLQ-C30) supplemented by the neuro-oncological module (QLQ-BN20) and the Euro Quality of Life questionnaire (EQ5D-5L) 24 months
Secondary Health - Related Economics For the Health Related Economics (HR-E) analyses, the EQ5D - 5L questionnaire will be used in conjunction with the Productivity Costs Questionnaire (iPCQ) and the Medical Consumption Questionnaire (iMCQ). These questionaires are optional. 24 months
See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Recruiting NCT04843085 - Proteomic Characterization of Aggressive Oligodendrogliomas
Completed NCT02903784 - Neural Basis of Language Processing N/A
Completed NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma Phase 2
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Completed NCT02530320 - Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Phase 2
Terminated NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Phase 2
Active, not recruiting NCT02549833 - Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Phase 1
Recruiting NCT06038760 - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Recruiting NCT05624736 - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting NCT05345002 - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Phase 2
Completed NCT03900689 - Social Determinants of Health in Glioblastoma Population
Completed NCT02747407 - Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Recruiting NCT04970615 - Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated NCT01836549 - Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Phase 2
Recruiting NCT03796273 - Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Early Phase 1
Terminated NCT00031538 - Genetic Analysis of Brain Tumors
Completed NCT01609790 - Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Phase 2
Not yet recruiting NCT05513859 - Investigational Imaging Technique During Brain Surgery N/A